Robotic surgery for gallbladder cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Robocop trial is an international, multi-centre, single-blinded, randomized controlled trial comparing robotic-assisted radical cholecystectomy to open resection for patients with suspected or confirmed gallbladder cancer. Patients will be randomly assigned in a 1:1 ratio to either surgical approach within an enhanced recovery setting. The primary goal is to evaluate the time to functional recovery, while secondary outcomes include hospital stay duration, resection margins, lymph node retrieval, postoperative complications, quality of life, and associated costs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with radiologically suspected or confirmed (≥T1b) incidental gallbladder cancer after cholecystectomy with an indication of radical cholecystectomy, without the need for resection of extrahepatic bile ducts, as decided at a multidisciplinary team conference.
* Patient sufficiently fit to undergo radical cholecystectomy according to surgeon and anaesthesiologist.

Exclusion Criteria:

* Previous extensive surgery in the upper abdomen (for example open liver surgery)
* Pregnancy
* Intraoperative findings of dissemination (patient is then excluded after randomization)
* Intraoperative findings of the need to perform resection of extrahepatic bile ducts (patient is then excluded after randomization).
* Intraoperative findings leading to a simple cholecystectomy only (patient is then excluded after randomization)

Where it's running

• Region Stockholm
  Stockholm, Sweden Recruiting

Study contacts

• Principal investigator: Christian Sturesson, PhD — Region Stockholm, Stockholm, Sweden
• Study coordinator: Christian Sturesson, PhD
• Email: christian.sturesson@regionstockholm.se
• Phone: 0046812380000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga‑FAPI PET/CT imaging for biliary tract cancers

  We will test whether 68Ga‑FAPI PET/CT scans can find and stage gallbladder cancer and intrahepatic cholangiocarcinoma more accurately than standard FDG PET/CT in adults with suspected or known disease.

  Recruiting Tata Memorial Centre · Mumbai, Maharashtra · NCT07337850

• Blood test using cfDNA methylation to screen for biliary tract cancers

  This study tests whether a blood test that reads cfDNA methylation can detect biliary tract cancers early in adults with or suspected of having these cancers.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07176962

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Anti-blood-vessel therapy after immunotherapy for advanced bile duct or gallbladder cancer.

  This study will test whether giving the anti-angiogenic drug anlotinib after first-line immunotherapy helps people with advanced bile duct or gallbladder cancer live longer without their disease getting worse.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07025174

• Combination treatment for advanced intrahepatic cholangiocarcinoma and gallbladder cancer

  This study is testing a new combination treatment for people with advanced bile duct and gallbladder cancer to see if it can help them respond better to therapy and possibly become eligible for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tia · NCT06852287

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.